CHURCHILL MANAGEMENT Corp Acquires 1,460 Shares of Danaher Co. (NYSE:DHR)

CHURCHILL MANAGEMENT Corp lifted its holdings in Danaher Co. (NYSE:DHR) by 2.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 51,111 shares of the conglomerate’s stock after purchasing an additional 1,460 shares during the quarter. CHURCHILL MANAGEMENT Corp’s holdings in Danaher were worth $11,732,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the stock. FMR LLC lifted its holdings in shares of Danaher by 15.8% in the 3rd quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock valued at $6,566,116,000 after buying an additional 3,217,631 shares during the period. Legal & General Group Plc raised its position in Danaher by 2.4% during the second quarter. Legal & General Group Plc now owns 5,964,031 shares of the conglomerate’s stock worth $1,490,112,000 after acquiring an additional 139,989 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Danaher by 3.0% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,097,986 shares of the conglomerate’s stock valued at $1,417,342,000 after buying an additional 148,251 shares in the last quarter. Fisher Asset Management LLC boosted its stake in shares of Danaher by 2.6% in the third quarter. Fisher Asset Management LLC now owns 4,552,640 shares of the conglomerate’s stock worth $1,265,725,000 after acquiring an additional 116,299 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its stake in Danaher by 17.6% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock worth $996,141,000 after purchasing an additional 535,254 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Stock Performance

Shares of DHR opened at $237.78 on Thursday. The stock has a market capitalization of $171.74 billion, a P/E ratio of 45.38, a P/E/G ratio of 4.32 and a beta of 0.83. Danaher Co. has a 12-month low of $222.53 and a 12-month high of $281.70. The firm’s 50 day moving average is $235.27 and its 200-day moving average is $253.56. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.57 by $0.14. The firm had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The business’s revenue for the quarter was up 3.1% on a year-over-year basis. During the same period in the prior year, the business earned $2.02 EPS. Equities research analysts anticipate that Danaher Co. will post 7.5 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.45%. The ex-dividend date is Friday, December 27th. Danaher’s payout ratio is 20.61%.

Wall Street Analyst Weigh In

A number of analysts have issued reports on DHR shares. Royal Bank of Canada cut their target price on Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. Citigroup dropped their price objective on Danaher from $305.00 to $285.00 and set a “buy” rating for the company in a research note on Monday, January 6th. Robert W. Baird reduced their target price on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. UBS Group lowered their price objective on Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a research report on Wednesday, October 23rd. Finally, Wolfe Research raised Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 target price on the stock in a report on Thursday, October 31st. Six investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Danaher presently has a consensus rating of “Moderate Buy” and a consensus price target of $286.80.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.